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Summary
QUESTIONS UNDER STUDY: High blood pressure, the
single leading health risk factor worldwide, contributes
greatly to morbidity and mortality. This study aimed to add
to the understanding of diagnosed and undiagnosed high
blood pressure in Switzerland and to evaluate adherence to
hypertension guidelines.
METHODS: Included were 3962 participants from the first
(2001–2003) and second (2010–2011) follow-ups of the
population-based Swiss Cohort Study on Air Pollution and
Lung and Heart Disease in Adults. High blood pressure
was defined as blood pressure ≥140/90 mm Hg and the
prevalence of doctor-diagnosed hypertension was based on
questionnaire information.
RESULTS: High blood pressure was found in 34.9% of
subjects, 49.1% of whom were unaware of this condition;
30.0% had doctor-diagnosed hypertension and, although
82.1% of these received drug treatments, in only 40.8%
was blood pressure controlled (<140/90 mm Hg). Sub-
stantial first-line beta-blocker use and nonadherence to
comorbidity-specific prescription guidelines were ob-
served and remained mostly unexplained. Age-adjusted
ACEI angiotensin converting-enzyme inhibitor
ARB angiotensin II receptor blocker
BB beta-blocker
BP blood pressure
CI confidence interval
DALY disability adjusted life year
ddHT doctor-diagnosed hypertension
HBP high blood pressure
OR odds ratio
SAPALDIA Swiss Cohort Study on Air Pollution and Lung and
Heart Disease in Adults
SSH Swiss Society of Hypertension
rates of unawareness and uncontrolled hypertension were
more than 20% higher than in the USA.
CONCLUSIONS: There is room for improvement in man-
aging hypertension in Switzerland. Population-based ob-
servational studies are essential for identifying and evalu-
ating unmet needs in healthcare; however, to pinpoint the
underlying causes it is imperative to facilitate linkage of
cohort data to medical records.
Key words: hypertension; blood pressure; prevalence;
awareness; treatment; control; guideline adherence;
Switzerland
Introduction
High blood pressure (HBP) accounts for 17.8% of deaths
and 7.0% of disability-adjusted life years (DALYs) glob-
ally, making it the number one single risk factor worldwide
[1]. In Switzerland, a country with universal healthcare
coverage and which ranks fourth in per capita total health
expenditure [2], an estimated 27% of adults have hyperten-
sion [3] and 18.7% of deaths and 7.9% of DALYs [4] are
attributed to this risk factor. The burden of disease related
to hypertension is mainly mediated by ischaemic heart dis-
ease and stroke [5].
In Switzerland, concordant national data on hypertension
prevalence from surveys, primary care or hospital dis-
charge statistics are available [6]. However, when hyper-
tension prevalence is based on diagnosed hypertension, the
true prevalence of hypertension may be underestimated
owing to the often asymptomatic nature of HBP. Regional
estimates of undiagnosed hypertension in Switzerland vary
from 6 to 13% of the adult population, this range may in
part be explained by differences in age distributions and
the age-standardisation of the reported rates in the respect-
ive studies [7, 8]. However, current nationwide population-
based data covering varied geographical and cultural re-
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 1 of 11
gions is lacking. Once diagnosed, one may expect uniform-
ity in managing hypertension in a small and economically
well-to-do country like Switzerland with its own guidelines
for the management of hypertension [9]; however, national
information on guideline adherence is scarce.
Managing hypertension according to guidelines remains
a practical challenge, especially in a poly-morbid, poly-
medicated population where more than one conflicting
guideline may apply and drugs with antihypertensive prop-
erties are used for the treatment of other diseases.
Moreover guidelines worldwide differ [9–12], and more
than one document may influence clinical practice in a giv-
en country.
This study aimed to describe the prevalence, awareness,
treatment and control of hypertension in Switzerland, and
to evaluate adherence to the Swiss Society of Hypertension
(SSH) guidelines in regards to drug choice.
Methods
Study population
This analysis was based on the Swiss Cohort Study on
Air Pollution and Lung and Heart Disease in Adults
(SAPALDIA), with participants originally recruited from
the general adult population in eight communities covering
the range of geographical (urban, rural, alpine) and cultural
(German-, French-, and Italian-speaking) conditions in
Switzerland [13]. Beginning with a baseline assessment in
1991, the first and second follow-ups were in 2001–2003
(SAPALDIA 2) and 2010–2011 (SAPALDIA 3), respect-
ively. Blood pressure (BP) measurement was added from
SAPALDIA 2 onwards. Ethical approval was obtained
from the Swiss Academy of Medical Sciences’ Central
Ethical Committee and the appropriate cantonal ethics
committees. Participants gave written informed consent.
This analysis focused on data from SAPALDIA 3 using
elements from SAPALDIA 2 for added depth. Included
were SAPALDIA 2 and 3 participants for whom all relev-
ant data were available: that is, questionnaire information
on morbidities, medications, lifestyle and clinical informa-
tion on blood pressure, weight and height (n = 3962) (see
appendix, supplementary fig. S1).
Questionnaire information
Morbidity data were collected during an in-person inter-
view with the use of questionnaires. Questions included:
“Has a doctor ever told you that you have one of the fol-
lowing diseases?” followed by a list of diseases including
hypertension, arrhythmia, asthma, etc. Only participants
with asthma who had also had at least one attack in the last
year or were taking asthma medication were considered as
asthmatics in this analysis. Participants with atrial fibril-
lation were defined as those with arrhythmia taking either
vitamin K antagonists or platelet aggregation inhibitors
(excluding heparin). All medications taken were listed in
a questionnaire. Drugs considered asantihypertensive were
angiotensin converting-enzyme inhibitors (ACEIs), an-
giotensin II receptor blockers (ARBs), beta-blockers
(BBs), calcium antagonists, diuretics, renin inhibitors and
other hypertensives with anatomical therapeutic chemical
(ATC) code C02. Questionnaire information on smoking
(never, former, current), alcohol consumption (number of
standard glasses/day), fruit and vegetable intake (number
of servings/day) and physical activity (minutes of moderate
and/or vigorous activity/week) was also collected.
Neighbourhood-level socioeconomic index, a 0- to
100-point scale based on education, head of household
occupation, rent and crowding derived from 2000 census
data [14], was allocated on the basis of SAPALDIA 2
home address. Degree of urbanisation (high, medium, low)
was allocated on the basis of home address according to
the European-wide degree of urbanisation (DEGURBA)
classification for local administrative units – usually com-
munes.
Clinical measurements
Blood pressure was measured twice by trained field work-
ers using an automatic device (705CP, OMRON, Tokyo,
Japan) with a cuff of appropriate size (after having meas-
ured arm circumference) and using the Riva-Rocci method,
in the sitting position after minimum 10 minutes rest, on
the left arm, with 3 minutes between measurements. Blood
pressure values are expressed as mean systolic and mean
diastolic pressures in mm Hg. Height and weight were
measured when the participants were without shoes and
wearing light clothing.
High blood pressure and doctor-diagnosed
hypertension
HBP was defined as systolic blood pressure ≥140 and/
or diastolic blood pressure ≥90 mm Hg, simply described
as HBP or “blood pressure ≥140/90” from now onwards.
Doctor-diagnosed hypertension (ddHT) was based on the
following question “Has a doctor ever told you that you
have hypertension?” HBP unawareness refers to those with
HBP but not ddHT and is expressed as a percentage of
those with HBP. Uncontrolled ddHT refers to those with
ddHT and HBP and is expressed as a percentage of those
with ddHT.
Guideline adherence
Guideline adherence was evaluated in those with ddHT
and was based on the Swiss Society of Hypertension 2009
guidelines [15] in effect at SAPALDIA 3 data collection.
Specific recommendations are described in table 1. Current
Swiss Society of Hypertension guidelines are available on
their website [9].
Recommended lifestyle goals were combined in a lifestyle
score, one point attributed for each recommendation suc-
cessfully met; not smoking, low risk alcohol consumption
(≤1 glass/day by women and ≤2 glasses/day by men) [16],
fruit/vegetable consumption ≥5/day, body mass index <25
kg/m2 and regular physical activity (150 minutes of moder-
ate or 60 minutes of vigorous activity per week alone or in
an equivalent combination with moderate activity).
Statistical analysis
Unless noted otherwise, data presented are from
SAPALDIA 3. Descriptive results are presented as number
and percent for categorical variables and as median and
interquartile range for quantitative variables. Chi-squared
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tests, t-tests and Wilcoxon rank-sum tests were used for
bivariate analysis as appropriate. Several multivariable lo-
gistic regression models were constructed using the back-
wards stepwise method to assess determinants of the fol-
lowing outcomes; ddHT, HBP, HBP unawareness, uncon-
trolled ddHT and new onset of cardiovascular events
(angina pectoris, myocardial infarction, heart failure and
stroke). Covariates systematically considered in all models
were: sex, age, language, degree of urbanisation, education,
neighbourhood-level socioeconomic index and lifestyle
score. Covariates additionally considered in some models
were: systolic blood pressure, HBP, HBP unawareness, un-
controlled ddHT and a binomial variable for concomitant
cardiovascular or metabolic disease (dyslipidaemia, dia-
betes, angina pectoris, myocardial infarction, heart failure
or stroke). As neighbourhood-level socioeconomic index
was available only for SAPALDIA 2 addresses, in sens-
itivity analyses the participants who had moved during
the SAPALDIA 2–3 interval were excluded to determine
if observed associations persisted. Since association pat-
terns did not differ, results are not presented. All p-values
<0.05 were considered statistically significant. Statistical
analysis was performed using STATA 13 (StataCorp. 2013.
Stata: Release 13. Statistical Software. College Station,
TX: StataCorp LP.)
Results
Available characteristics of included and excluded parti-
cipants at baseline and the first and second follow-ups are
presented in supplementary table S1. In comparison with
the excluded participants, our study sample was better edu-
cated, included fewer smokers and more physically act-
ive individuals having less HBP and/or ddHT, but having
similar prevalences of other comorbidities. The analytical
sample consisted of 3962 participants, 50% men and 50%
women, with a median age of 60.4 years, ranging from 37
to 81 years old.
High blood pressure and hypertension; prevalence,
awareness, and control
Of the 3986 participants, 34.9% had HBP (blood pressure
≥140/90) and 30.0% had ddHT. These two groups over-
lapped to some degree resulting in 47.1% having HBP and/
or ddHT. Of those with HBP, 49.1% did not report a dia-
gnosis of hypertension, and were therefore considered un-
aware, representing 17.1% of the analytical sample as a
whole. Of those with ddHT, 59.2% had HBP and were
therefore considered to have uncontrolled ddHT. Prevalen-
ce of HBP, ddHT, and HBP and/or ddHT was statistically
significantly higher in men than in women (p <0.001).
Prevalence data including sex differences are described in
figure 1. Even after controlling for age, lifestyle score,
presence of concomitant cardiovascular or metabolic dis-
ease, language, education level, degree of urbanisation and
neighbourhood level socioeconomic level, men were more
likely to have HBP (odds ratio [OR] 1.59, 95% confidence
interval [CI] 1.38–1.85, p <0.001) and ddHT (OR 1.38,
95% CI 1.18–1.62, p <0.001).
Systolic blood pressure ≥160 and/or diastolic blood pres-
sure ≥100 mm Hg was found in 19.5%, 33.0%, 27.0% and
20.8% of those with ddHT, uncontrolled ddHT, HBP and
HBP unawareness, respectively. These blood pressure val-
ues correspond to grade 2 or 3 hypertension. Detailed dis-
Figure 1
Prevalence of high blood pressure and doctor-diagnosed
hypertension, stratified by gender (% [95%CI])
p-values for sex differences determined with chi-squared tests, * p
<0.001, a p = 0.262, b p = 0.104
CI = confidence interval; ddHT = doctor diagnosed hypertension;
HBP = high blood pressure
Table 1: Selected 2009 Swiss Society of Hypertension guidelines [15].
Lifestyle improvements for all
Smoking cessation, limited alcohol consumption, a diet rich in fruits and vegetables and poor in salt, physical activity, weight control
Drug treatment
First-line drugs: ACEI, ARB, CA, diuretics
Alternative drug: beta-blockers (not recommend as a first-line drug as some studies show them to be ineffective in reducing stroke and coronary heart disease and to have
negative effects on lipid and glucose metabolism. However, beta-blockers are permitted to initiate therapy when certain comorbidities are present) [26]
Comorbidity specific treatement, recommended drugs
Coronary heart disease
Heart failure
Diabetes
Dyslipidaemia
Migraines
Asthma
ACEI, ARB, BB, CA
ACEI, ARB, BB, diuretic
ACEI, ARB, BB*, CA
ACEI, ARB, CA
BB
avoid BB*
Target blood pressure <140/90 in general
<130/80 in those with diabetes or kidney disease†
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = beta-blocker; CA = calcium antagonist
* Beta-blockers are not recommended in people with abnormal glucose tolerance, but permitted in overt diabetes, blood pressure reduction being the main goal. The
careful use of highly cardioselective beta-blockers is permitted in individuals with stable asthma if a good indication to beta-blocker use is present and with adequate
monitoring [26].
† Note, the 2015 Swiss guidelines differ, placing target blood pressure at <140/85 in those with diabetes or kidney disease [9].
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tribution of blood pressure severity in these groups is de-
scribed in table 2.
Determinants of high blood pressure unawareness
A multivariable logistic regression with HBP unawareness
as outcome was adjusted for age, sex, SAPALDIA 2 systol-
ic blood pressure, presence of concomitant cardiovascular
or metabolic disease, language, education level, degree of
urbanisation, neighbourhood socioeconomic status and
lifestyle score. Those more likely to be unaware of HBP
were men (OR 1.42, 95% CI 1.09–1.86, p = 0.010), young-
er participants (OR 0.88 per 10-year increase, 95% CI
0.78–1.00, p = 0.047), those with lower systolic blood pres-
sure (OR 0.90 per 2-mm Hg increase, 95% CI 0.88–0.92,
p <0.001 ), those without concomitant cardiovascular dis-
ease (OR 2.35, 95% CI 1.82–3.02, p <0.001 ), those with
lower neighbourhood-level socioeconomic status (OR 0.86
per 10-point increase, 95% CI 0.75–0.99, p = 0.031) and
those with higher lifestyle score (OR 1.36 per point in-
crease, 95% CI 1.19–1.55, p <0.001).
Target blood pressure and determinants of
uncontrolled hypertension
Based on our blood pressure measurements, the general
target blood pressure of <140/90 mm Hg was reached by
40.8% of the 1188 participants with ddHT. Of the 232 par-
ticipants with ddHT and diabetes or kidney disease, only
23.7% (18.6–29.7%) reached the treatment goal of <130/80
mm Hg.
A multivariable logistic regression with uncontrolled ddHT
as outcome was adjusted for age, sex, SAPALDIA 2 systol-
ic blood pressure, presence of concomitant cardiovascular
or metabolic disease, lifestyle score, language, education
level, degree of urbanisation and neighbourhood-level so-
cioeconomic status. More likely to have uncontrolled ddHT
were those with higher SAPALDIA 2 systolic blood pres-
sure (OR 1.08 per 2-mm Hg increase, 95% CI 1.06–1.10, p
<0.001), and those with lower lifestyle score, though only
with borderline statistical significance (OR 0.88 per point
increase, 95% CI 0.77–1.00, p = 0.057).
Outcomes of high blood pressure, unawareness and
uncontrolled hypertension
To determine the outcomes of HBP, HBP unawareness and
uncontrolled ddHT and to evaluate possible overestimation
of HBP due to the white coat effect (blood pressure meas-
urements only being available from the study centre visits),
we assessed the 10-year morbidity in the respective groups
from SAPALDIA 2. Controlling for age and sex, the OR
for developing angina pectoris during the SAPALDIA 2–3
interval in those with HBP compared with those with nor-
mal blood pressure in SAPALDIA 2 was 2.2 (1.2–4.1, p =
0.013). Similarly, ORs for developing myocardial infarc-
tion, heart failure, stroke and any of these four cardiovascu-
lar diseases were 3.3 (1.8–6.0, p <0.001), 2.5 (1.3–4.7, p =
0.004), 1.7 (0.9–3.2, p = 0.088) and 2.2 (1.6–3.1, p <0.001),
respectively. Adjusted for age and sex, the ORs of de-
veloping cardiovascular outcomes during the SAPALDIA
2–3 interval in those unaware compared with those aware
of their HBP at SAPALDIA 2 were for some outcomes
higher than one and for some lower than one but never
reached statistical significance. In contrast, after adjusting
for age and sex, the ORs of developing angina pectoris,
myocardial infarction, heart failure or stroke during the
SAPALDIA 2–3 interval were higher than one in those
with uncontrolled compared to those with controlled ddHT
at SAPALDIA 2, although not reaching statistical signific-
ance.
Hypertension pharmacotherapy
Overall, 82.1% of the 1188 participants with ddHT took
blood pressure-lowering agents, 42.3% of these took one
drug, 36.3% took two and 21.4% took three or more. Of
those taking at least two, 65.0% used a combined fixed
dose preparation. When compared with subjects with drug-
treated ddHT, those with non-drug-treated ddHT had high-
er lifestyle scores (Wilcoxon rank-sum p = 0.030), and
higher mean systolic blood pressure (147.9 mm Hg
[145.5–150.3] compared with 142.6 mm Hg
[141.5–143.8]) and diastolic blood pressure (87.7 mm Hg
[86.4–89.0] compared with 81.3 mm Hg [80.6–82.0], p
≤0.001).
Beta-blockers as a first-line drug
Though the Swiss Society of Hypertension did not recom-
mend beta-blockers as a first-line drug, except in the pres-
ence of some comorbidities, 100 (24.2%, 20.4–28.7%) of
the 412 hypertensive participants on monotherapy took
beta-blockers. Providing possible explanations, 8.0% had
coronary heart disease, 1.0% had heart failure, 9.0% had
atrial fibrillation, 7.0% had diabetes, 16.0% had migraines
and 34.0% had at least one of the above listed comorbidit-
ies. First-line beta-blocker prescription did not vary by age
(p = 0.385).
Table 2: Distribution of blood pressure measurements, by hypertension- or high blood pressure-group (data are proportion of group with 95% confidence interval).
Blood pressure
(mm Hg)
In those with ddHT
(n = 1188)
In those with uncontrolled
ddHT
(n = 703)
In those with HBP
(n = 1381)
In those unaware of their HBP
(n = 678)
Normal
<140/90
40.8
(38.1–43.7)
– – –
Grade 1*
140–159 / 90–99
39.6
(36.9–42.5)
67.0
(63.4–70.4)
73.0
(70.6–75.3)
79.2
(76.0–82.1)
Grade 2*
160–179 / 100–109
15.5
(13.5–17.7)
26.2
(23.0–29.6)
21.8
(19.7–24.1)
17.3
(14.6–20.3)
Grade 3*
≥180/110
4.0
(3.1–5.3)
6.8
(5.2–9.0)
5.2
(4.2–6.5)
3.5
(2.4–5.2)
ddHT = doctor diagnosed hypertension; HBP = high blood pressure
*Grades 1–3 represent systolic blood pressure and/or diastolic blood pressure within the respective ranges. Participants were allocated to a group based on highest level
of blood pressure, be it systolic or diastolic.
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Comorbidity specific treatment
Antihypertensive drug classes recommended on the basis
of comorbidity as well as the distribution of guideline ad-
herence are described in table 3. Of those with drug treated
ddHT and dyslipidaemia (n = 406), 18.2% were taking
neither ACEIs, ARBs nor calcium antagonists, despite re-
commendations. Only 33.8% of this seeming guideline
nonadherence could be explained by the presence of other
comorbidities where beta-blockers or diuretics were per-
mitted or are commonly prescribed (coronary heart disease,
heart failure, atrial fibrillation, diabetes, migraines or kid-
ney disease). Beta-blockers were prescribed in 8 (19.5%)
individuals with both asthma and hypertension. All eight
had asthma medication and in six the prescribed beta-
blockers were cardioselective. Of the possible explanations
for beta-blocker prescription (coronary heart disease, heart
failure, migraines or atrial fibrillation), only one of these
asthmatic participants had migraines and one had atrial fib-
rillation.
Discussion
High blood pressure and hypertension: prevalence,
awareness and control
In this analysis from the population-based SAPALDIA co-
hort 50% had either ddHT or blood pressure ≥140/90.
Thirty percent had ddHT, among whom 60% had uncon-
trolled ddHT. Some uncontrolled ddHT may reflect a white
coat effect or may have been intentional, accounting for
orthostatic hypotension. Still, rates of uncontrolled HBP
were high and the distribution of blood pressure severity
was equally surprising, as 21% of those unaware of their
HBP had measurements ≥160/100 mm Hg. Furthermore,
recent research indicates that the 140 mm Hg target is not
low enough; a 120 mm Hg target results in significantly
lower cardiovascular mortality and morbidity in nondia-
betic patients without previous stroke but at high risk of
cardiovascular events [17]. The association of both HBP
and uncontrolled ddHT with long-term cardiovascular out-
comes reinforces the validity of our measurements and un-
derlines the importance of early diagnosis and proper treat-
ment. Similar odds of cardiovascular outcomes between
those aware and unaware of their HBP were expected as
HBP is harmful regardless of having a diagnosis or not.
After definitions were harmonised, our results were com-
parable to other Swiss data on hypertension prevalence,
awareness and control [3, 7, 18] (see supplementary table
S2). When comparing age-specific harmonised definitions
from our study and 2009–2010 US data [19], we found that
the prevalence of HBP and/or antihypertensive drug intake
were similar, whereas awareness and control were respect-
ively 20.0–37.4% and 23.8–34.4% lower in our data (see
supplementary table S3). This is consistent with the liter-
ature which shows lower awareness and control in Europe
compared to the USA [20–22].
In the current study, we assessed the prevalence, determ-
inants and outcomes of HBP (defined as blood pressure
≥140/90 mm Hg) and hypertension as diagnosed by a doc-
tor. The white coat effect, which should be excluded by
performing 24-hour or home blood pressure measurement,
and masked hypertension may have led to respectively
over- or underestimation of HBP. Because of their long-
term participation in SAPALDIA, our sample may be
healthier and more compliant than the general population.
Our results might thus underestimate the true population
prevalence of diagnosed or undiagnosed hypertension. On
the other hand, our blood pressure values are the mean of
two measurements from a single visit and may overestim-
ate an individual’s usual blood pressure [23]. Still, 140/90
remains an arbitrary cut-off across a spectrum of above-
normal blood pressure within which cardiovascular risk in-
creases [24]. Approximately 50% of DALYs attributed to
above-normal blood pressure occur below this 140/90 cut-
off [5].
Groups at higher risk
Identifying groups at higher risk for HBP unawareness
and uncontrolled ddHT is challenging; accordingly, the res-
ults from the literature differ. In our study, younger age,
male sex, healthier lifestyle, lower neighbourhood-level so-
cioeconomic status and lower SAPALDIA 2 systolic blood
pressure were associated with HBP unawareness. Uncon-
trolled hypertension was associated with higher
SAPALDIA 2 systolic blood pressure. These findings are,
in part, echoed in studies from Switzerland and elsewhere
[7, 8, 19]. Differences in healthcare utilisation, drug pre-
scription or adherence trends may explain these results, al-
though we were unable to asses this in the current study.
Table 3: Comorbidity-specific guideline adherence and nonadherence in those with drug treated, doctor-diagnosed hypertension (n = 975).
Comorbidity (number of participants)
and recommended drug classes
Only recommended drugs prescribed
n (%)
Mix of recommended and
nonrecommended drugs prescribed
n (%)
Only nonrecommended drugs
prescribed
n (%)
Coronary heart disease (n = 86)
ACEI, ARB, BB, CA
49 (57.0%) 36 (41.9%) 1 (1.2%)
Heart failure (n = 35)
ACEI, ARB, BB, diuretic
25 (71.4%) 8 (22.9%) 2 (5.7%)
Diabetes (n = 156)
ACEI, ARB, BB, CA
68 (43.6%) 82 (52.6%) 6 (3.8%)
Dyslipidaemia (n = 406)
ACEI, ARB, CA
118 (29.1%) 214 (52.7%) 74 (18.2%)
Migraines (n = 73)
BB
16 (21.9%) 17 (23.3%) 40 (54.8%)
Asthma (n = 41)
avoid BB
33 (80.5%) 5 (12.2%) 3 (7.3%)
ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; BB = betablocker; CA = calcium antagonist; ddHT = doctor-diagnosed hypertension
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Pharmacotherapy
High rates of uncontrolled hypertension despite high treat-
ment rates might be explained by the complexity of clinical
situations, or by physicians’ inertia in changing drugs or in-
creasing dose even when blood pressure targets remain un-
met as previously described in Switzerland [25]. Also, drug
compliance is challenging because hypertension is chronic
and often asymptomatic. In some cases fixed-combination
antihypertensive preparations may be preferred to remedy
this issue [10].
Several practical challenges arise in aligning pharmaco-
therapy to guidelines. Guidelines differ worldwide, and
several documents potentially influence practitioners in a
given country. Even within one document, conflicting re-
commendations may apply to the same individual. Also,
drug choice is influenced by efficacy, tolerance, security
and price. Lastly, antihypertensive drugs are used in the
treatment of other conditions independently of hyperten-
sion. These elements may explain some of the seeming
guideline nonadherence.
In our analysis, nonadherence was particularly high regard-
ing beta-blockers. The Swiss Society of Hypertension did
not recommend beta-blockers as first-line drugs since stud-
ies report them to be ineffective in reducing stroke and
coronary heart disease and to have negative effects on lip-
id and glucose metabolism [26]. Similarly, US and UK
guidelines [11, 12] did not generally encourage beta-block-
ers as first-line drugs. However, the European Society of
Hypertension guidelines considered beta-blockers as ap-
propriate for initial treatment [10, 27]. Since 24.2% of first-
line drugs in our data were beta-blockers and their pre-
scription remained largely unexplained by comorbidities,
Swiss doctors were possibly unaware of the Swiss Soci-
ety of Hypertension recommendation or were following
European guidelines.
In the recommendation to avoid beta-blockers when
asthma is present, the Swiss Society of Hypertension does
nuance the statement [26]. However, a recent review re-
commends prudence, even when using cardioselective
beta-blockers in hypertensive asthmatics [28]. Twenty per-
cent of asthmatics with hypertension were receiving beta-
blockers (mainly cardioselective), but clear indications for
beta-blocker treatment were not evident in our data.
Needed action in hypertension management
While there is room for improvement in overall guideline
adherence, one main concern is the high prevalence of
uncontrolled hypertension. A European-wide survey, in-
cluding Switzerland, showed that physicians underestimate
their role in unmet blood pressure targets [29]. What should
be done about guideline nonadherence, particularly in re-
gard to unmet blood pressure goals? Redon et al. propose
some practical solutions: increasing both awareness of the
harmful nature of hypertension and patient accountability
and simplifying treatment with combined preparations
[30].
Strengths and limitations
Participants in the SAPALDIA cohort are characterised in
great detail and reflect the geographical and cultural di-
versity of Switzerland. Yet the Swiss health care system is
highly fragmented and its organisation does not allow for
efficient access to objective information on medical dia-
gnoses and treatment. In this study, diagnoses and medica-
tion intake were self-reported. The study was not designed
to address particularly the issue of uncontrolled hyperten-
sion, so information on regularity of blood pressure meas-
urements, drug compliance, or reasons for nonadherence to
medical recommendations is lacking. Therefore we cannot
fully explain the observed unawareness and noncontrol of
hypertension; however, their high prevalence is unlikely to
be due to bias or participant behaviour alone.
Conclusions
Prevalence of HBP, ddHT, HBP unawareness and uncon-
trolled ddHT were high. Nonadherence to comorbidity-
specific drug prescription guidelines remained high and
largely unexplained, particularly concerning the use of
beta-blockers as first-line drugs. For HBP, a major car-
diovascular risk factor, there is still room for substantial
improvement from prevention to diagnosis, treatment and
control, even in Switzerland, a high-income country. Our
results underline the value of population-based cohorts for
the identification and characterisation of potential unmet
needs in healthcare practice. To further improve the value
of these cohorts, it would be essential to facilitate efficient
linkage of cohort data to medical records.
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Appendix: Supplementary figure and tables
Figure S1
Selection of study population.
BP = blood pressure; SAPALDIA = Swiss Cohort Study on Air Pollution and Lung and Heart Disease in Adults.
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Table S1: Characteristics of included and excluded participants at baseline, and first and second follow up.
SAPALDIA 1
included
SAPALDIA 1
excluded
p-value SAPALDIA 2
included
SAPALDIA 2
excluded
p-value SAPALDIA 3
included
SAPALDIA 3
excluded
p-value
Participants 3962 5689 3962 4085 3962 2126
Men 1984 (50.1%) 2761 (48.5%) 0.136 1984 (50.1%) 1883 (46.1%) <0.001 1984 (50.1%) 913 (42.9%) <0.001
Age years (IQR) 41.2 (31.6,
48.9)
42.2 (32.1,
51.6)
0.003 52 (42.5, 59.8) 53.5 (43.7,
62.8)
<0.001 60.4 (50.9,
68.0)
60.1 (50.5,
69.5)
0.447
German-speaking
French-speaking
Italian-speaking
2148 (54.2%)
1267 (32.0%)
546 (13.8%)
2758 (48.5%)
2004 (35.2%)
925 (16.3%)
<0.001 2148 (54.2%)
1267 (32.0%)
546 (13.8%)
2106 (51.6%)
1317 (32.2%)
662 (16.2%)
0.005 2150 (54.3%)
1278 (32.3%)
534 (13.5%)
663 (55.9%)
351 (29.6%)
171 (14.4%)
0.214
Highest education
Primary
Secondary#
Tertiary
424 (10.7%)
2753 (69.6%)
781 (19.7%)
1199 (21.2%)
3644 (64.3%)
826 (14.6%)
<0.001 168 (4.2%)
2559 (64.6%)
1235 (31.2%)
534 (13.1%)
2698 (66.1%)
847 (20.8%)
<0.001 168 (4.2%)
2559 (64.6%)
1235 (31.2%)
246 (11.6%)
1421 (66.9%)
457 (21.5%)
<0.001
Neighbourhood-level socio-
economic index (0- to 100-point
scale)
64.2 (57.5,
71.0)
63.4 (55.6,
70.3)
0.001 64.2 (57.5,
71.0)
64 (56.4, 71.1) 0.557
Degree of urbanisation
High
Medium
Low
1187 (30.0%)
2244 (56.8%)
523 (13.2%)
1485 (37.1%)
2146 (53.6%)
370 (9.2%)
<0.001 1121 (28.3%)
2277 (57.5%)
564 (14.2%)
605 (30.0%)
1165 (57.8%)
246 (12.2%)
0.065
Blood pressure
Systolic BP, mm Hg (IQR) 124.5 (112.5,
138.0)
127 (114.0,
139.5)
<0.001 131.5 (120,
144.5)
131 (120.0,
143.5)
0.748
Diastolic BP, mm Hg (IQR) 79.0 (72.0,
86.5)
79.0 (72.0,
87.0)
0.481 78.5 (72.0,
85.0)
79.0 (72.0,
85.5)
0.303
HBP and/or ddHT 1265 (31.9%) 1090 (41.2%) <0.001 1866 (47.1%) 724 (58.3%) <0.001
HBP (BP ≥140/90)
Unaware
1032 (26.0%)
677 (65.6%)
728 (29.2%)
445 (61.1%)
0.006
0.055
1381 (34.9%)
678 (49.1%)
331 (34.8%)
173 (55.4%)
0.977
0.043
ddHT
Uncontrolled
588 (14.8%)
355 (60.4%)
645 (18.7%)
283 (58.4%)
<0.001
0.502
1188 (30.0%)
703 (59.2%)
532 (28.4%)
139 (58.6%)
0.225
0.881
Lifestyle characteristics
Never smokers
Former smokers
Current smokers
1960 (49.5%)
945 (23.9%)
1052 (26.6%)
2269 (39.9%)
1236 (21.7%)
2180 (38.3%)
<0.001 1825 (46.1%)
1269 (32.0%)
868 (21.9%)
1569 (38.5%)
1255 (30.8%)
1248 (30.6%)
<0.001 1787 (45.1%)
1542 (38.9%)
633 (16.0%)
859 (40.8%)
764 (36.3%)
480 (22.8%)
<0.001
Low risk alcohol consumption
≤1 glass/day in women
≤2 glasses/day in men
1916 (96.9%)
1701 (85.7%)
690 (94.0%)
460 (87.5%)
0.118
1910 (96.6%)
1759 (88.2%)
560 (96.2%)
456 (89.8%)
0.340
Fruit and vegetable intake ≥5/day 867 (21.9%) 530 (20.3%) 0.132 916 (23.1%) 243 (22.1%) 0.464
Sufficient physical activity 2913 (73.5%) 1745 (67.5%) <0.001 2967 (74.9%) 707 (67.6%) <0.001
BMI <25 kg/m2
≥25 to <30 kg/m2
≥30 kg/m2
2773 (70.1%)
1002 (25.3%)
178 (4.5%)
3528 (63%)
1581 (28.2%)
490 (8.8%)
<0.001 1934 (48.8%)
1472 (37.2%)
556 (14.0%)
1132 (42.9%)
1001 (38.0%)
503 (19.1%)
<0.001 1669 (42.1%)
1568 (39.6%)
725 (18.3%)
395 (40.1%)
395 (40.1%)
194 (19.7%)
0.437
Comorbidities (self-reported doctor-diagnosed)
Angina pectoris 66 (1.7%) 62 (1.8%) 0.721 82 (2.1%) 39 (2.8%) 0.103
Myocardial infarct 47 (1.2%) 54 (1.5%) 0.181 92 (2.3%) 75 (4%) <0.001
Heart failure 47 (1.2%) 40 (1.5%) 0.233 61 (1.5%) 64 (3.4%) <0.001
Atrial fibrillation 119 (3.0%) 27 (2%) 0.040
Stroke 41 (1.0%) 48 (1.4%) 0.164 68 (1.7%) 24 (1.7%) 0.953
Dyslipidaemia 339 (38.7%) 94 (46.3%) 0.045 994 (25.1%) 375 (20.3%) <0.001
Diabetes 90 (2.3%) 151 (4.4%) <0.001 282 (7.1%) 162 (8.6%) 0.044
Asthma 137 (3.5%) 155 (3.8%) 0.384 172 (4.3%) 76 (3.7%) 0.208
Migraines 289 (7.3%) 276 (8.0%) 0.267 289 (7.3%) 138 (8.3%) 0.182
BMI = body mass index; BP = blood pressure; ddHT = doctor-diagnosed hypertension; HBP = high blood pressure; IQR = interquartile range (25th, 75th percentile)
# including apprenticeships
Data are presented as number and percent or median and interquartile range; p-values were obtained with median tests or chi-squared tests. The number for comparison
was minimum 1073, due to missing information.
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Table S2: Comparison of hypertension prevalence between SAPALDIA 3 and other Swiss data.
SAPALDIA 3 2010–2011
Percent (95% CI)
Other Swiss data
Percent (95% CI)
Prevalence ddHT 30.0 (28.6–31.4) 27#
Prevalence of HT: HBP and/or taking antihypertensive drugs 48.5 (46.9–50.0) 36 (35–38)*
Awareness: those with ddHT among those with HBP and/or taking antihypertensive drugs 58.7 (56.4–60.8) 63 (61–65)*
Control: those with BP<140/90 among those with HBP and/or taking antihypertensive drugs 28.0 (26.1–30.1) 23 (21–25)*
Here definitions of “hypertension”, “awareness” and “control” were adopted from the CoLaus study.
# Swiss Health Survey 2012, aged 15–75+ years [1]
* CoLaus 2003–2006, aged 35–75 years [2] SAPALDIA 3 participants were aged 37–81 years
BP = blood pressure; CI = confidence interval; ddHT = doctor-diagnosed hypertension; HT = hypertension; HBP = high blood pressure (blood pressure ≥140/90 mm Hg)
Table S3: Prevalence comparison between SAPALDIA 3 and United States data.
Age strata (years) SAPALDIA 3
2010–2011
Percent (95% CI)
United States
NHANES [3] 2009–2010
Percent (95% CI)
Prevalence: HBP and/or taking antihypertensive drugs 40–59
60+
32.2 (30.1–34.5)
65.3 (63.2–67.3)
30.3 (26.3–34.3)
66.7 (63.1–70.2)
Awareness: those with ddHT among those with HBP and/or taking
antihypertensive drugs
40–59
60+
46.7 (42.6–50.8)
64.0 (61. –66.6)
84.1 (80.4–87.7)
84.0 (80.8–87.1)
Control: those with BP<140/90 among those with HBP and/or taking
antihypertensive drugs
40–59
60+
21.3 (18.1–24.8)
31.1 (28.6–33.6)
55.7 (51.0–60.5)
54.9 (50.9–58.9)
Here definitions of “awareness” and “control” were adpoted from the NHANES.
BP = blood pressure; CI = confidence interval; ddHT = doctor-diagnosed HT; HBP = high blood pressure (blood pressure ≥140/90 mm Hg); NHANES = National Health and
Nutrition Examination Survey.
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Figures (large format)
Figure 1
Prevalence of high blood pressure and doctor-diagnosed hypertension, stratified by gender (% [95%CI])
p-values for sex differences determined with chi-squared tests, * p <0.001, a p= 0.262, b p = 0.104
CI = confidence interval; ddHT = doctor diagnosed hypertension; HBP = high blood pressure
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